Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Rating) EVP Antoine Yver sold 6,500 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $4.45, for a total transaction of $28,925.00. Following the completion of the sale, the executive vice president now owns 783,066 shares of […]
Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Rating) was the target of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 1,740,000 shares, a drop of 10.3% from the March 31st total of 1,940,000 shares. Based on an average trading volume of 188,800 shares, the […]
Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Rating) EVP Antoine Yver sold 6,800 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $4.42, for a total value of $30,056.00. Following the completion of the sale, the executive vice president now directly owns 789,566 shares […]
Should You Buy or Sell Centessa Pharmaceuticals Stock? Get The Latest CNTA Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentationBOSTON and LONDON, Nov. 03, 2022 (GLOBE